Research Topics
Species | H J AlterSummaryAffiliation: National Institutes of Health Country: USA Publications
| Collaborators
|
Detail Information
Publications
The hazards of blood transfusion in historical perspectiveHarvey J Alter
Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD, USA
Blood 112:2617-26. 2008..These infectious and noninfectious hazards are reviewed briefly in the context of their historical evolution...- A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infectionYing Huang
Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
Proc Natl Acad Sci U S A 104:985-90. 2007.... - Anti-viral state segregates two molecular phenotypes of pancreatic adenocarcinoma: potential relevance for adenoviral gene therapyVladia Monsurro
Department of Pathology, University of Verona Medical School, Verona, Italy
J Transl Med 8:10. 2010..Pancreatic ductal adenocarcinoma (PDAC) remains a leading cause of cancer mortality for which novel gene therapy approaches relying on tumor-tropic adenoviruses are being tested... 
Emerging infectious diseases that threaten the blood supplyHarvey J Alter
Infectious Diseases Section and Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD 20892, USA
Semin Hematol 44:32-41. 2007..However, to approach near-zero infectious disease risk for emerging and re-emerging pathogens, new strategies such as pathogen inactivation or multi-pathogen microarray technology will need to be developed or refined...
Pathogen reduction: a precautionary principle paradigmHarvey J Alter
Department of Transfusion Medicine, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
Transfus Med Rev 22:97-102. 2008..This can be done if there is sufficient will to do it...- Emerging, re-emerging and submerging infectious threats to the blood supplyH J Alter
Department of Transfusion Medicine, Warren Grant Magnuson Clinical Center, Bethesda, USA
Vox Sang 87:56-61. 2004 - The unexpected outcomes of medical research: serendipity and the Australia antigen. Blumberg BS, Alter HJ, Visnich S. A new antigen in leukemia sera [J Am Med Assoc 1965;191:541-546]Harvey J Alter
National Institutes of Health, MSC 1184, Bethesda, MD 20892, USA
J Hepatol 39:149-52. 2003 - Genomic and molecular evolutionary analysis of a newly identified infectious agent (SEN virus) and its relationship to the TT virus familyY Tanaka
Department of Transfusion Medicine, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland, USA
J Infect Dis 183:359-67. 2001..This taxonomic classification suggests that these circular ssDNA viruses probably evolved from a common ancestor virus... - SEN virus infection in patients with hepatocellular carcinomaS Momosaki
Division of Emerging and Transfusion Transmitted Diseases, Food and Drug Administration, Bethesda, MD, USA
J Viral Hepat 12:435-8. 2005..SEN-V was found in only one of seven HCC patients without HBV (without HBsAg or HBV DNA) or HCV and thus does not appear to be an important cause of 'cryptogenic' HCC... - Association between SEN virus infection and hepatitis C in JapanT Umemura
Second Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan
J Infect Dis 184:1246-51. 2001..SENV is a common infection that appears to have transmission routes and age-related prevalence that are distinct from those of HCV. No evidence was found that SENV caused hepatitis or worsened the course of hepatitis C... - Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative studyL B Seeff
The Veterans Affairs Medical Centers, Washington, DC, USA
Hepatology 33:455-63. 2001..Liver-related mortality attributable to chronic hepatitis C, though low (<3%), is significantly higher among the cases. Among living patients originally HCV-infected, 23% have spontaneously lost HCV RNA... - Highly quantitative serological detection of anti-cytomegalovirus (CMV) antibodiesPeter D Burbelo
Neurobiology and Pain Therapeutics Section, Laboratory of Sensory Biology, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland 20892, USA
Virol J 6:45. 2009..Currently, there is a need for improved quantitative serological tests to document seropositivity with high sensitivity and specificity... - Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis CKittichai Promrat
The Liver Diseases Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
Gastroenterology 124:352-60. 2003..The roles of other disease-associated chemokine system polymorphisms have not been evaluated in hepatitis C virus infection... - Reversibility of experimental rabbit liver cirrhosis by portal collagenase administrationBo Jin
Department of Digestive Diseases, Military Medical Graduate School, Beijing, China
Lab Invest 85:992-1002. 2005..Potential application to humans is premature, but feasible, if these findings are confirmed in additional animal studies... - Prospective study of hepatitis C viral infection as a risk factor for subsequent B-cell neoplasiaCharles S Rabkin
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20852, USA
Blood 99:4240-2. 2002..Although acquisition in later life cannot be ruled out, these prospective data do not support a substantial role of chronic HCV infection in the etiology of B-cell neoplasia... - SEN virus: response to interferon alfa and influence on the severity and treatment response of coexistent hepatitis CTakeji Umemura
Second Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan
Hepatology 35:953-9. 2002..SENV infection had no apparent influence on the severity of HCV-related liver disease or the HCV response to IFN-alpha. SENV was sensitive to IFN-alpha therapy and the majority of patients had a sustained virologic response... - Genomic scale analysis of racial impact on response to IFN-alphaZoltan Pos
Infectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, and Center for Human Immunology, National Institutes of Health, Bethesda, MD 20892, USA
Proc Natl Acad Sci U S A 107:803-8. 2010.... - Evaluation of commercially available and in-house reverse transcription-PCR assays for detection of hepatitis G virus or GB virus CX Forns
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 0740, USA
J Clin Microbiol 35:2698-702. 1997..In summary, RT-nested PCR and a commercially available RT-PCR assay for HGV or GBV-C gave concordant results for 96% of the patients tested... - A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decadesYasuhito Tanaka
Department of Transfusion Medicine, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
Proc Natl Acad Sci U S A 99:15584-9. 2002..These estimates of viral spread time are consistent with epidemiologic observations and predict that the burden of HCC in the U.S. will increase in the next two to three decades, possibly to equal that currently experienced in Japan... - Prevalence of SEN viruses among injection drug users in the San Francisco Bay areaRuth M Pfeiffer
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, Maryland 20852, USA
J Infect Dis 188:13-8. 2003..05; 95% CI, 2.62-18.95). SENV strains are common among San Francisco Bay area IDUs, and prevalence varies demographically within this group... - Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infectionKazumoto Murata
Liver Diseases Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
Proc Natl Acad Sci U S A 100:6753-8. 2003.... - Quantitative analysis of anti-hepatitis C virus antibody-secreting B cells in patients with chronic hepatitis CTakeji Umemura
Department of Transfusion Medicine, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892-1184, USA
Hepatology 43:91-9. 2006..Measurement at the single-cell level suggests that humoral immunity plays a minor role in recovery from HCV infection and that B-cell immunity is strongest in those with persistent infection... - SEN virus: epidemiology and characteristics of a transfusion-transmitted virusJun Akiba
Division of Emerging and Transfusion Transmitted Diseases, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA
Transfusion 45:1084-8. 2005..Nevertheless, SEN-V appears to be transmitted by transfusion, and further studies may reveal more about its role in the future... - SEN virus infection and its relationship to transfusion-associated hepatitisT Umemura
The Department of Transfusion Medicine, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892-1184, USA
Hepatology 33:1303-11. 2001..The vast majority of SEN-V-infected recipients did not develop hepatitis... - The natural history of acute hepatitis C: clinical presentation, laboratory findings and treatment outcomesR Loomba
Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA
Aliment Pharmacol Ther 33:559-65. 2011..Acute hepatitis C has variable modes of presentation and frequently results in chronic infection. Its optimal management has yet to be defined... - Stability of HCV-RNA level and its lack of correlation with disease severity in asymptomatic chronic hepatitis C virus carriersA E Yeo
Department of Transfusion Medicine, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA
J Viral Hepat 8:256-63. 2001..5 logs; (iii) did not correlate with either the extent of inflammation or degree of fibrosis. In contrast, there was a strong association between ALT level and the histological severity of liver disease... - DNA immunization encoding the secreted nonstructural protein 3 (NS3) of hepatitis C virus and enhancing the Th1 type immune responseX Jiao
Department of Transfusion Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20982, USA
J Viral Hepat 11:18-26. 2004..Our study indicates that DNA immunization with a secreted form of HCV/NS3 is an effective means of inducing primary Th1 immune responses in the murine model... - Induction of potent cellular immune response in mice by hepatitis C virus NS3 protein with double-stranded RNABo Jin
Infectious Disease Section, Department of Transfusion Medicine, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, MD, USA
Immunology 122:15-27. 2007..This study highlighted a promising formulation for inducing an efficient cellular immune response against HCV that has potential for HCV vaccine development... - Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasmaPei Zhang
Division of Hematology, Center for Biologics Evaluation and Research, Food and Drug Administration, 29 Lincoln Drive, Bethesda, MD 20892, USA
Proc Natl Acad Sci U S A 104:8449-54. 2007.... - Induction of multispecific Th-1 type immune response against HCV in mice by protein immunization using CpG and Montanide ISA 720 as adjuvantsQi Qiu
Department of Transfusion Medicine, Warren G Magnuson Clinical Center, National Institutes of Health, Building 10, Room 1C711, 9000 Rockville Pike, Bethesda, MD 20892 1184, USA
Vaccine 26:5527-34. 2008..The use of adjuvants appears critical to the induction of Th1 immune responses during HCV vaccination with recombinant proteins... - Parvovirus B19 infection transmitted by transfusion of red blood cells confirmed by molecular analysis of linked donor and recipient samplesMei Ying W Yu
Division of Hematology, Center for Biologics Evaluation and Research, FDA, Warren Grant Magnuson Clinical Center, NIH, Bethesda, Maryland 20892, USA
Transfusion 50:1712-21. 2010..However, reports of transmission by single-donor blood components are rare. In this prospective study, paired donor-recipient samples were used to investigate the transfusion risk... - Association of interleukin-15-induced peripheral immune activation with hepatic stellate cell activation in persons coinfected with hepatitis C virus and HIVRobert D Allison
Department of Transfusion Medicine, National Institutes of Health, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892 1876, USA
J Infect Dis 200:619-23. 2009..Future strategies that reduce immune activation and HSC activation may delay progression of liver fibrosis... - Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activityPei Zhang
Division of Hematology and Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, MD 20892, USA
Proc Natl Acad Sci U S A 106:7537-41. 2009..Our studies contribute to understanding the mechanisms of antibody-mediated neutralization and interference and provide a practical approach to the development of more potent and broadly reactive hepatitis C immune globulins... - Enhanced hepatitis C virus NS3 specific Th1 immune responses induced by co-delivery of protein antigen and CpG with cationic liposomesXuanmao Jiao
Department of Transfusion Medicine, Warren G. Magnuson Clinical Center, Building 10, Room 1C711, National Institutes of Health, Bethesda, MD 20892-1184, USA
J Gen Virol 85:1545-53. 2004..In conclusion, liposomes co-encapsulating HCV NS3 and CpG are a good candidate vaccine to induce strong Th1 immune responses against hepatitis C viruses... - Investigation of SEN virus infection in patients with cryptogenic acute liver failure, hepatitis-associated aplastic anemia, or acute and chronic non-A-E hepatitisTakeji Umemura
Department of Transfusion Medicine, Warren Grant Magnuson Clinical Center, National Heart, Lung, Blood Institute, National Institutes of Health, Bethesda, Maryland 20892 1184, USA
J Infect Dis 188:1545-52. 2003..The severity of acute or chronic hepatitis A, B, or C was not influenced by coexisting SENV infection. No etiological role for SENV in the cause of cryptogenic hepatitis could be demonstrated... - Vigorous hepatitis C virus-specific CD4+ and CD8+ T cell responses induced by protein immunization in the presence of Montanide ISA720 plus synthetic oligodeoxynucleotides containing immunostimulatory cytosine-guanine dinucleotide motifsFuminaka Sugauchi
Department of Transfusion Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
J Infect Dis 193:563-72. 2006..A DNA boost after a protein prime--a reversal of the conventional approach--may provide an alternative path to the development of an effective HCV vaccine... - Observation of positive selection within hypervariable regions of a newly identified DNA virus (SEN virus)(1)Takeji Umemura
Department of Transfusion Medicine, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
FEBS Lett 510:171-4. 2002..32 x 10(-4) per site per year. Since this rate is close to RNA viruses and higher than other DNA viruses, the SEN-V might be replicated by machinery with poor or no proofreading function... - Human monoclonal antibodies that react with the E2 glycoprotein of hepatitis C virus and possess neutralizing activityDarren J Schofield
Hepatitis Viruses Section, Laboratory of Infectious Diseases, NIAID, National Institutes of Health, Bethesda, MD 20892-8009, USA
Hepatology 42:1055-62. 2005..In conclusion, one or more of these monoclonal antibodies may be useful in preventing infections by HCV belonging to genotype 1 or 2, the most medically important genotypes worldwide... - Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune responseKazushi Sugimoto
Division of Gastroenterology, Department of Medicine, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA 19104, USA
Hepatology 37:590-9. 2003..AA ethnicity is associated with a more robust antiviral CD4 T-cell response than CA ethnicity, although these T cells are limited in direct virus or disease control due to their dysfunctional nature... - Evolution of hepatitis C viral quasispecies and hepatic injury in perinatally infected children followed prospectivelyPatrizia Farci
Department of Medical Sciences, University of Cagliari, SS 554 Bivio Sestu, 09042 Cagliari, Italy
Proc Natl Acad Sci U S A 103:8475-80. 2006..The sequences reported in this paper have been deposited in the GenBank database (accession nos. DQ 504441-DQ 507112)... - Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcomePatrizia Farci
Department of Medical Sciences, University of Cagliari, 09124 Cagliari, Italy
Proc Natl Acad Sci U S A 99:3081-6. 2002.... - A reduction in selective immune pressure during the course of chronic hepatitis C correlates with diminished biochemical evidence of hepatic inflammationKousuke Hanada
National Institute of Genetics, Yata 1111, Mishima, Shizuoka, Japan
Virology 361:27-33. 2007..This observation may be applicable to other viruses characterized by a slow rate of disease progression... - Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortalityYasuhito Tanaka
Department of Clinical Molecular Informative Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
Gastroenterology 130:703-14. 2006..CONCLUSIONS: These findings strongly suggest that the initial spread time of HCV is associated with the progression dynamics of HCC in each area, irrespective of genotype... - Clinical spectrum and histopathologic features of chronic hepatitis C infection in childrenParvathi Mohan
Department of Gastroenterology and Nutrition, Children s National Medical Center, Washington, DC 20010, USA
J Pediatr 150:168-74, 174.e1. 2007..To define the natural history and outcomes of children infected with hepatitis C virus (HCV) at birth or in early childhood... - The epidemiology of transfusion-associated hepatitis C in a children's hospitalNaomi L C Luban
Division of Laboratory Medicine and Pathology, Children s National Medical Center, Washington, DC 20010, USA
Transfusion 47:615-20. 2007..To determine the prevalence of HCV infection and risks associated with acquisition of HCV, a single-institution lookback study was performed... - HCV natural history: the retrospective and prospective in perspectiveHarvey J Alter
J Hepatol 43:550-2. 2005 - Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet lightLily Lin
Cerus Corporation, Concord, California, USA
Transfusion 45:580-90. 2005..A photochemical treatment (PCT) process with amotosalen-HCl and long-wavelength ultraviolet light (UVA), which cross-links nucleic acids, was developed to inactivate viruses and other pathogens in PLT concentrates... - Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infectionKazushi Sugimoto
Department of Medicine, University of Pennsylvania and Philadelphia Veterans Affairs Medical Center, Philadelphia, PA 19104, USA
Hepatology 38:1437-48. 2003..The high frequency of CD4(+)CD25(+) regulatory T cells and their suppression of HCV-specific CD8 T cells ex vivo suggests a novel role for regulatory T cells in HCV persistence... - Strain-specific T-cell suppression and protective immunity in patients with chronic hepatitis C virus infectionKazushi Sugimoto
Department of Medicine, GI Division, University of Pennsylvania, and Philadelphia VAMC, A212 Medical Research, PVAMC, University and Woodland Avenues, Philadelphia, PA 19104, USA
J Virol 79:6976-83. 2005..These findings provide new insights into host-virus interactions in HCV infection that have implications for vaccine development... - Frequency and duration of plasma CMV viremia in seroconverting blood donors and recipientsW Lawrence Drew
UCSF Mount Zion Medical Center, University of California and the Blood Centers of the Pacific, USA
Transfusion 43:309-13. 2003..To explain this residual risk, evidence of cell-free viremia was sought in seroconverting and seroprevalent blood donors and seroconverting transfusion recipients by means of a plasma-based assay for CMV DNA... - Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralizationTroels K H Scheel
Copenhagen Hepatitis C Program CO HEP, Department of Infectious Diseases and Clinical Research Centre and Department of Clinical Microbiology, Copenhagen University Hospital, DK 2650 Hvidovre, Denmark
Proc Natl Acad Sci U S A 105:997-1002. 2008..Thus, the JFH1 intergenotypic recombinants will be of importance for future studies of HCV neutralization and accelerate the development of passive and active immunoprophylaxis...